Delivering an immune therapy into tumours instead of intravenously reduces adverse effects

Nature, Published online: 29 April 2026; doi:10.1038/d41586-026-01193-5 In people with advanced skin cancer, injecting low doses of an anticancer immunotherapy directly into tumours, rather than administering high doses intravenously, reduced severe immune toxicity while preserving antitumour efficacy. Pre-existing antitumour immunity predicted clinical benefit most strongly, and profiling fresh tissue provided response biomarkers faster than conventional diagnostics did.